Axovant Sciences Ltd., a company without a finished product or a dime of sales, has an almost $3 billion valuation after its public-market debut. The IPO shows the staggering potential for any company that can develop a successful Alzheimer’s treatment.
Dr. Kent Brantly was awarded the Dr. Nathan Davis International Award in Medicine from the American Medical Association for his service in Liberia during last summer’s Ebola outbreak.
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.
New research from the Mayo Clinic is bringing back a long-running debate over whether drug companies like Eli Lilly and Biogen are focusing on the right target in developing therapies to treat the disease.
A proposal aimed at giving terminally ill patients in Indiana easier access to experimental drugs not yet on pharmacy shelve is about to become law.
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Major drugmakers—including Indianapolis-based Eli Lilly and Co.—the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or cure.
An Indiana Senate committee is considering a bill that would give terminally ill patients easier access to experimental drugs that have not received full federal approval. Indiana is one of nearly two dozen states that are considering the legislation.
Paris-based drugmaker Sanofi had revenue of $8.4 billion from Lantus last year. It lost U.S. patent protection this month and will lose exclusive rights in Europe in May.
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Indianapolis hospital leaders have spent the past two months ironing out a plan to deal with any cases of Ebola that emerge in Indiana. The plan is aimed at ensuring effective care while also minimizing the need to bring other hospital services to a virtual halt while patients are under care.
Eli Lilly and Co. would be a logical acquirer for the maker of a drug that could treat agitation in Alzheimer’s patients.
Gov. Mike Pence appeared on a webcast with health care workers Thursday to talk about Ebola and the state’s preparations should the disease arrive in the state.
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
Design can help thwart antibiotic-resistant bacteria
Major Health Partners will construct an $89 million hospital on the north edge of Shelbyville, after nearly a decade of shifting services to that location. According to the Shelbyville News, Major’s board voted Sept. 22 to build a 300,000-square-foot facility in the Intelliplex technology park along Interstate 74 and move from downtown Shelbyville. Construction on the project could begin as early as next month and take about two years to complete. Major first revealed detailed plans for the hospital six weeks ago, but the project could not go forward until the board’s 6-0 vote. The hospital will include 56 beds, all in private rooms, and 38 outpatient observation beds. Major’s current hospital has 72 beds in mostly semi-private rooms. When completed, the new complex will also have four operating rooms and house 57 physicians and a staff of about 930.
Researchers at Purdue University and the Indiana University School of Medicine have received a $3.7 million grant to study how blueberries reduce bone loss in postmenopausal women. The five-year grant from the National Institutes of Health's National Center for Complementary and Alternative Medicine will pay for researchers to conduct human trials aimed at finding the most effective varieties and dosage levels of blueberriers for reducing bone loss. “This is one of the most compelling avenues to pursue in natural products research because blueberries would be a new alternative to osteoporosis drugs and their side effects,” said Connie Weaver, the head of Purdue’s department of nutrition science and one of the grant recipients.
Bernard Health, a health benefits brokerage firm based in Tennessee, opened its second retail store in Indianapolis last week. The 1,270-square-foot store is downtown on Pennsylvania Street, just north of Washington Street. Bernard, which now employs seven here in Indianapolis, opened its first local retail store in the Nora neighborhood in 2012 and now has 12 stores nationwide. For a fee, Bernard helps individuals and small businesses evaluate and purchase health benefits. It is one of several new models being tried out by benefits brokers in Indiana to adapt to new rules and opportunities under Obamacare.
The Indiana University School of Medicine received gifts totaling $1 million on the 40th anniversary of Dr. Larry Einhorn’s discovery of a drug combination therapy that nearly cured testicular cancer. In September 1974, Einhorn, a professor at the IU medical school, first tested the cancer drug cisplatin with two other cancer drugs—a combination that boosted survival rates from the cancer from about 20 percent to 95 percent. According to the medical school, 300,000 patients have survived testicular cancer after receiving the drug therapy Einhorn discovered. The most famous is Lance Armstrong, the cycling champion stripped of his victories after admitting to doping. The gifts will help launch a gene sequencing program among survivors so future patients can be given treatments that reduce side effects and complications. Half the donated money came from A. Farhad Moshiri of Monaco, who previously donated $2 million to IU. Another $300,000 will come from the children of local real estate magnate Sidney Eskenazi and his wife, Lois.
Indianapolis-based private investment company LDI Ltd. has acquired a small biotech manufacturer in a deal it says could be the launching point for many more acquisitions.
The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.
